Medtronic PLC $MDT Shares Sold by WestEnd Advisors LLC

WestEnd Advisors LLC lowered its position in shares of Medtronic PLC (NYSE:MDT) by 1.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 464,734 shares of the medical technology company’s stock after selling 8,573 shares during the quarter. Medtronic makes up approximately 1.0% of WestEnd Advisors LLC’s holdings, making the stock its 25th biggest holding. WestEnd Advisors LLC’s holdings in Medtronic were worth $44,261,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of MDT. 1248 Management LLC acquired a new stake in shares of Medtronic during the 1st quarter worth $26,000. Delos Wealth Advisors LLC purchased a new stake in Medtronic during the second quarter worth approximately $27,000. Tripletail Wealth Management LLC acquired a new stake in shares of Medtronic in the third quarter valued at about $34,000. GFG Capital LLC purchased a new stake in shares of Medtronic during the second quarter valued at approximately $36,000. Finally, True Wealth Design LLC grew its stake in shares of Medtronic by 49.8% during the second quarter. True Wealth Design LLC now owns 421 shares of the medical technology company’s stock valued at $37,000 after acquiring an additional 140 shares in the last quarter. 82.06% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

MDT has been the subject of a number of research reports. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Medtronic in a report on Monday, December 29th. Wells Fargo & Company lifted their target price on Medtronic from $100.00 to $114.00 and gave the stock an “overweight” rating in a report on Wednesday, November 19th. Barclays lifted their target price on shares of Medtronic from $109.00 to $111.00 and gave the stock an “overweight” rating in a research report on Thursday, November 20th. Truist Financial reduced their price target on shares of Medtronic from $110.00 to $107.00 and set a “hold” rating for the company in a research report on Thursday, December 18th. Finally, The Goldman Sachs Group set a $111.00 price objective on shares of Medtronic and gave the company a “neutral” rating in a research report on Wednesday, November 19th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and twelve have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $109.94.

Medtronic Price Performance

MDT stock opened at $96.03 on Monday. The stock has a market cap of $123.11 billion, a PE ratio of 25.88, a price-to-earnings-growth ratio of 2.53 and a beta of 0.71. Medtronic PLC has a 1 year low of $79.55 and a 1 year high of $106.33. The stock has a 50-day moving average price of $97.65 and a two-hundred day moving average price of $94.13. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, beating analysts’ consensus estimates of $1.31 by $0.05. The business had revenue of $8.96 billion for the quarter, compared to analysts’ expectations of $8.86 billion. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The firm’s revenue for the quarter was up 6.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities analysts forecast that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 16th. Shareholders of record on Friday, December 26th will be issued a $0.71 dividend. The ex-dividend date is Friday, December 26th. This represents a $2.84 annualized dividend and a yield of 3.0%. Medtronic’s dividend payout ratio is presently 76.55%.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).